Edition:
United States

ImmunoCellular Therapeutics Ltd (IMUC.A)

IMUC.A on American Stock Exchange

2.93USD
27 Mar 2017
Change (% chg)

$0.33 (+12.69%)
Prev Close
$2.60
Open
$2.68
Day's High
$2.97
Day's Low
$2.68
Volume
45,959
Avg. Vol
14,415
52-wk High
$13.60
52-wk Low
$1.87

IMUC.A

Chart for IMUC.A

About

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company's cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is... (more)

Overall

Beta: 0.46
Market Cap(Mil.): $9.26
Shares Outstanding(Mil.): 3.44
Dividend: --
Yield (%): --

Financials

  IMUC.A Industry Sector
P/E (TTM): -- 47.98 29.94
EPS (TTM): -8.13 -- --
ROI: -106.53 -2.56 13.01
ROE: -158.59 5.14 14.16

BRIEF-Immunocellular Therapeutics and Memgen announce letter of intent for potential joint immuno-oncology collaboration

* Immunocellular Therapeutics and Memgen announce letter of intent for potential joint immuno-oncology collaboration

Mar 23 2017

BRIEF-Immunocellular Therapeutics Q4 loss per share $1.36

* Immunocellular Therapeutics announces fourth quarter and full year 2016 financial results and provides corporate update

Mar 09 2017

BRIEF-Immunocellular Therapeutics provides update on ICT-107 phase 3 glioblastoma trial

* Immunocellular Therapeutics provides update on ICT-107 phase 3 glioblastoma trial and announces advances in stem-to-t-cell research program

Mar 06 2017

BRIEF-Immunocellular Therapeutics reports updated immune monitoring data from ICT-107 phase 2

* Immunocellular Therapeutics reports updated immune monitoring data from ICT-107 phase 2 trial in newly diagnosed glioblastoma at the society for neuro-oncology annual meeting 2016

Nov 21 2016

BRIEF-Immunocellular Therapeutics reports one-for-forty reverse stock split

* Immunocellular Therapeutics announces one-for-forty reverse stock split Source text for Eikon: Further company coverage:

Nov 16 2016

BRIEF-Immunocellular Therapeutics reports Q3 loss per share $0.04

* Immunocellular Therapeutics announces third quarter 2016 financial results and provides research and development update

Nov 10 2016

More From Around the Web

Earnings vs. Estimates